Growth Hormone Peptides
Explore how GH-related compounds differ in identity, human evidence and approved uses. The profiles below distinguish hormone responses from body-composition outcomes and long-term clinical benefit.
Category Overview
GH secretagogues stimulate hormone release; somatropin supplies growth hormone itself. Hormone activity, clinical benefit and product approval are different questions. The GH evidence guide compares the actual study populations and outcomes.
Tesamorelin has an approved role in excess abdominal fat associated with HIV lipodystrophy, with formulation-specific instructions and glucose, IGF-I and other precautions. It is not a general weight-loss medicine. Current Egrifta WR label.
The long-acting CJC-1295 trials measured GH and IGF-I, while an ibutamoren trial increased fat-free mass without demonstrated strength or function improvement. An acute GHRH/GHRP-6 synergy result does not establish a general CJC-1295/ipamorelin stack. CJC trials; ibutamoren trial; combination experiment.
FDA’s compound-specific safety record distinguishes substances, routes and information gaps. A research label, a hormone response or retained pulsatility is not a safety or approval determination. AOD-9604 is included as a related GH fragment, not relabeled as a secretagogue; its FDA assessment describes the larger oral obesity trial.
Explore GH-Related Profiles
Named Egrifta products reduce excess abdominal fat in adults with HIV-associated lipodystrophy. This is not general weight-loss approval; WR and SV formulations are not substitutable.
Long-acting, albumin-binding material studied in short human hormone trials. GH and IGF-I increased; those findings do not establish a standard muscle-gain or recovery result.
Non-DAC names are used inconsistently. Long-acting CJC-1295 findings cannot establish the identity, half-life or clinical performance of every non-DAC product.
Favorable selectivity findings come from animal experiments. Short human infusion and postoperative studies do not establish a long-term safety advantage or routine performance regimen.
Human hormone-response, diagnostic and acute food-intake research. Appetite stimulation and effects beyond GH matter; a higher GH response is not a proven muscle-gain advantage.
Human GH-response and acute GHRH-combination experiments. These findings do not establish an ideal appetite-treatment, bodybuilding stack or general safety ranking.
Mixed human findings include hormone release, partial reversible response attenuation, neutral body-composition results and exploratory cardiac and sleep studies. No universal potency or cycling winner is established.
An oral nonpeptide secretagogue. An older-adult trial increased fat-free mass without improved strength or function; glucose effects and a separate hip-fracture heart-failure signal limit broad reassurance.
Historical Geref products had pediatric treatment and diagnostic indications. Discontinuation was not for safety or effectiveness reasons; that history does not approve a current compounded anti-aging product.
A modified GH fragment, Tyr-hGH177–191, rather than a GH secretagogue. Favorable animal and early human signals coexist with a larger negative oral weight-loss trial; routine injection benefit is unestablished.
Research context: These entries cover different medicines, investigational compounds and a related GH fragment. Choose the exact product and clinical question before comparing findings. The linked profiles explain source, population and route limits; treatment decisions require the relevant prescribing and monitoring plan.